<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0025">
 <label>Table 5</label>
 <caption>
  <p>Monoclonal antibodies under the clinical trials.</p>
 </caption>
 <alt-text id="al0040">Table 5</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>S. no.</th>
    <th>Intervention/treatment</th>
    <th>Nature of the intervention</th>
    <th>Clinical trials</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">1.</td>
    <td>Emapalumab</td>
    <td>IL-6 inhibitor used for RA</td>
    <td>Phase 2/Phase 3
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324021" id="ir0070" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04324021</ext-link>)
    </td>
   </tr>
   <tr>
    <td>Anakinra</td>
    <td>Anti-interferon-gamma antibody used for the treatment of hemophagocytic lymphohistiocytosis</td>
    <td/>
   </tr>
   <tr>
    <td>2.</td>
    <td>Siltuximab</td>
    <td>IL-6 inhibitor used for cancer therapy</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04322188" id="ir0075" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04322188</ext-link>
    </td>
   </tr>
   <tr>
    <td>3.</td>
    <td>Tocilizumab</td>
    <td>IL-6 inhibitor is used to treat rheumatoid arthritis</td>
    <td>Phase 2
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04317092" id="ir0080" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04317092</ext-link>)
    </td>
   </tr>
   <tr>
    <td>4.</td>
    <td>Sarilumab</td>
    <td>Monoclonal antibody against IL-6R used in RA</td>
    <td>Phase 2
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04315298" id="ir0085" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04315298</ext-link>)
    </td>
   </tr>
   <tr>
    <td>5.</td>
    <td>PD-1 blocking antibody</td>
    <td>It Inhibits the T cell depletion in sepsis patients</td>
    <td>Phase 2
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04268537" id="ir0090" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04268537</ext-link>)
    </td>
   </tr>
   <tr>
    <td>6.</td>
    <td>Bevacizumab</td>
    <td>It is VEGR inhibitor and used to treat cancers</td>
    <td>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04305106" id="ir0095" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04305106</ext-link>)
    </td>
   </tr>
   <tr>
    <td>7.</td>
    <td>Tocilizumab</td>
    <td>IL-6R inhibitor is used treat RA</td>
    <td>Phase 3
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04320615" id="ir0100" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04320615</ext-link>)
    </td>
   </tr>
   <tr>
    <td>8.</td>
    <td>CD24Fc</td>
    <td>Innate checkpoint against the inflammatory response and immunomodulator</td>
    <td>Phase 3
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04317040" id="ir0105" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04317040</ext-link>)
    </td>
   </tr>
   <tr>
    <td rowspan="2">9.</td>
    <td>Recombinant human interferon Alpha-1b</td>
    <td>Immunomodulator</td>
    <td>Phase 3
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04320238" id="ir0110" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04320238</ext-link>)
    </td>
   </tr>
   <tr>
    <td>Thymosin alpha 1</td>
    <td>Immunomodulator</td>
    <td/>
   </tr>
   <tr>
    <td>10.</td>
    <td>Recombinant human interferon α1β</td>
    <td>Antiviral activity</td>
    <td>Early Phase 1
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04293887" id="ir0115" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04293887</ext-link>)
    </td>
   </tr>
   <tr>
    <td>11.</td>
    <td>Meplazumab</td>
    <td>Humanized anti-CD147 antibody</td>
    <td>Phase 1/Phase 2
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04275245" id="ir0120" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04275245</ext-link>)
    </td>
   </tr>
   <tr>
    <td>12.</td>
    <td>Intravenous immunoglobulin therapy</td>
    <td>Activates innate and adaptive immunity</td>
    <td>Phase 2/Phase 3
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04261426" id="ir0125" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04261426</ext-link>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
